Labyrinthin, The Tumor Marker Recognized By MCA 44-3A6: A Case For Pan-Tumor Markers As Targets To Treat Cancer
James A Radosevich, Michael Babich LabyRx Immunologic Therapeutics (USA) Limited, Sacramento, California, USACorrespondence: James A Radosevich 1009 Johnson Ct, Belvidere, IL 61008 Tel +1 530 330 5888Email jrados@labyrx.comAbstract: A paradigm shift is currently underway on the relationship between...
Main Authors: | Radosevich JA, Babich M |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2019-11-01
|
Series: | OncoTargets and Therapy |
Subjects: | |
Online Access: | https://www.dovepress.com/labyrinthin-the-tumor-marker-recognized-by-mca-44-3a6-a-case-for-pan-t-peer-reviewed-article-OTT |
Similar Items
-
DUXAP8 a Pan-Cancer Prognostic Marker Involved in the Molecular Regulatory Mechanism in Hepatocellular Carcinoma: A Comprehensive Study Based on Data Mining, Bioinformatics, and in vitro Validation
by: Yue C, et al.
Published: (2019-12-01) -
Long Noncoding RNA Linc00152 Functions as a Tumor Propellant in Pan-Cancer
by: Shouping Xu, et al.
Published: (2017-12-01) -
DNA Methylation Markers for Pan-Cancer Prediction by Deep Learning
by: Biao Liu, et al.
Published: (2019-10-01) -
Survival Outcomes of Pancreatic Intraepithelial Neoplasm (PanIN) versus Intraductal Papillary Mucinous Neoplasm (IPMN) Associated Pancreatic Adenocarcinoma
by: Timothy McGinnis, et al.
Published: (2020-09-01) -
Cross-cell DNA methylation annotation and analysis for pan-cancer study
by: Binhua Tang, et al.
Published: (2016-03-01)